Oscar Clinical Guideline: Immune Globulin Weight-Based Dosing Criteria (PG256, Ver. 2)

Immune Globulin Weight-Based Dosing Criteria

Summary

This policy provides evidence-based criteria for dosing optimization of immune globulin products. This policy applies to all immune globulin products administered intravenously (IVIG) or subcutaneously (SCIG), and is to be used in conjunction with the Plan's medical necessity criteria for both medical and

pharmacy benefits. The purpose is to ensure appropriate dosing based on clinical evidence while promoting safe and cost-effective use.

This policy establishes criteria for using ideal body weight (IBW) or adjusted body weight (adjBW) rather than total body weight (TBW) when calculating immune globulin doses in specific clinical scenarios. The use of adjusted body weight (adjBW) or ideal body weight (IBW) for dosing of immune globulin products in appropriate individuals is supported by clinical evidence and expert consensus. This includes, but are not limited to:

- Immune globulin products primarily distribute in the extracellular fluid space, with limited distribution in adipose tissue.
- Clinical studies demonstrate equivalent efficacy when using adjBW versus total body weight (TBW) for dosing in individuals whose actual weight significantly exceeds their IBW.
- Use of adjBW in appropriate individuals can:
    - Reduce the risk of adverse effects related to excessive dosing.
    - Maintain therapeutic efficacy while optimizing cost-effectiveness.
- Regular monitoring of clinical response and IgG levels ensures therapeutic adequacy when using adjusted dosing weights.

Definitions

"Adjusted Body Weight (adjBW)" is weight calculation that accounts for drug distribution in adipose tissue:

- adjBW = IBW + [0.4 × (TBW - IBW)]

"Body Mass Index (BMI)" is a calculated measure of body weight relative to height, expressed in kg/m², used to estimate body fat:

- BMI = weight (kg) / [height (m)]²

"Documentation" refers to written information, including but not limited to:

- Up-to-date chart notes, relevant test results, and/or relevant imaging reports to support diagnoses; or
- Prescription claims records, and/or prescription receipts to support prior trials of formulary alternatives.

"Ideal Body Weight (IBW)" is weight calculation based on height and gender using the Devine formula:

- Males: IBW = 50 kg + 2.3 kg for each inch over 5 feet
- Females: IBW = 45.5 kg + 2.3 kg for each inch over 5 feet

"IgG Trough Level" is the lowest concentration of immunoglobulin G in the blood, measured immediately before the next scheduled dose:

- For IVIG: Measured just prior to the next infusion.
- For SCIG: Measured at steady state, typically after 6-8 weeks of therapy.

"[s]" indicates state mandates may apply.

"Total Body Weight (TBW)" is the actual measured weight of the member.

Clinical Indications

Medical Necessity Criteria for Clinical Review

General Medical Necessity Criteria

The Plan considers Immune Globulin weight-based dosing medically necessary when ALL of the following criteria are met:

1. Documentation must include ALL of the following:
    a. Current height and weight (obtained within past 30 days); *and*
    b. Calculated Body Mass Index (BMI); *and*
    c. Calculated ideal body weight (IBW); *and*
    d. Proposed dose and frequency of administration; *AND*
2. Weight-based dose calculations must follow ONE (1) of the following:
    a. IF the member has aBMI <30 kg/m^2 OR whose actual body weight is ≤120% of IBW, dose will be calculated using actual body weight; *or*
    b. IF the member has a BMI ≥30 kg/m^2 OR whose actual body weight is >120% of IBW, dose will be calculated using adjusted body weight (adjBW), i.e., adjBW = IBW + [0.4 × (actual weight - IBW)]; *or*
    Note: For members who meet both criteria a and b, use the weight (actual body weight or adjBW) that is less restrictive.
    c. IF the member's actual body weight is less than IBW, dose will be calculated using actual body weight; *or*
    d. Dose may be calculated using actual body weight when ANY of the following apply:
        i. Pediatric members age ≤15 years; *or*
        ii. Pediatric members age ≤18 years and weight ≤50 kg; *or*
        iii. Clinical documentation supports medical necessity due to conditions affecting fluid/weight status (such as significant edema, fluid overload, or other volume status abnormalities); *or*
        iv. Clinical documentation supports actual body weight dosing, despite having a BMI ≥30 kg/m^2 OR in those whose actual body weight is >120% of IBW due to prior insufficient clinical response; *AND*
3. For members transitioning from IVIG to SCIG, initial SCIG dose should be calculated based on previous IVIG dose using appropriate conversion factor per FDA labeling.

If the above criteria are met, the requested product may be approved for the requested duration or according to one of the following durations, whichever is lesser:[s]

- Up to 12-months when authorized in conjunction with approved medical necessity criteria, whichever is lesser*; or*
- Up to 3 months for dose optimization during initiation/titration.

Continued Care

Medical Necessity Criteria for Subsequent Clinical Review

Subsequent General Medical Necessity Criteria

The Plan considers Immune Globulin weight-based dosing medically necessary when recent clinical documentation (within past 30 days) supports ALL of the following:

1. Current weight and height measurements; *AND*
2. Positive clinical response to therapy at current dose, as demonstrated by at least ONE (1) of the following:
    a. Maintenance of appropriate IgG trough levels for the indication; *or*
    b. Reduction in frequency or severity of infections compared to baseline; *or*
    c. Improvement or stabilization of disease-specific symptoms or validated clinical scores; *or*
    d. Reduction in disease-related hospitalizations or healthcare utilization; *AND*
3. Ongoing adherence to the weight-based dosing requirements specified in the Medical Necessity Criteria for Clinical Review (e.g., using IBW or adjBW when appropriate).

If the above reauthorization criteria are met, the requested product will be authorized for up to 12 months (*or in alignment with the approved medical necessity criteria authorization timeframe, whichever is less*).[s]

Dosing Considerations

A. Dose rounding requirements:
    1. Final calculated dose should be rounded to the nearest vial size.
    2. Combination of vial sizes should be used to minimize waste. When combining multiple vial sizes, select the combination that minimizes waste without risking significant underdosing or overdosing.
    3. If dose cannot be rounded to available vial sizes, clinical rationale must be provided.

    Note: While dose rounding to nearest vial size minimizes waste, clinicians should consider that underdosing may result in subtherapeutic levels and compromised efficacy, while overdosing may increase adverse effect risks. Document clinical rationale if rounding significantly deviates from calculated dose.

B. Maximum dose requirements:
    1. The total monthly dose must not exceed the maximum FDA-approved or guideline-supported dosing for the specific indication.

2. New dose requests above standard limits should be supported by valid clinical justification (e.g., subtherapeutic IgG levels despite adherence and confirmed appropriate administration).

Experimental or Investigational / Not Medically Necessary[s]

Weight-based dosing for immune globulin products for any of the following scenarios is considered not medically necessary by the Plan:

- Use of actual body weight for dose calculations in members >120% of IBW without documented clinical necessity (e.g., fluid overload, significant edema, lack of prior positive clinical outcome).
- Dose calculations that exceed maximum FDA-approved dosing for the indication without supporting clinical evidence.
- Weight-based dosing that deviates from published compending, dosing guidelines or evidence-based recommendations without adequate clinical justification for a requested indication.
- Use of non-optimal vial combinations resulting in significant product waste when more efficient dose rounding options are available.
- Continued use of initial weight-based dosing when documented clinical response indicates need for dose adjustment.

Applicable Billing Codes

Service(s) name	
CPT/HCPCS Codes considered medically necessary if criteria are met:	
Code	*Description*
J1459	Privigen Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg
J1551	Cutaquig Injection, immune globulin (cutaquig), 100 mg
J1552	Alyglo Injection, immune globulin (alyglo), 500 mg)
J1553	Yimmugo Injection, immune globulin (yimmugo), 100 mg)
J1554	Asceniv Injection, immune globulin (asceniv), 500 mg

J1555	Cuvitru Injection, immune globulin (cuvitru), 100 mg
J1556	Bivigam Injection, immune globulin (bivigam), 500 mg
J1557	Gammaplex Injection, immune globulin, (gammaplex), intravenous, non-lyophilized (e.g., liquid), 500 mg
J1558	Xembify Injection, immune globulin (xembify), 100 mg
J1559	Hizentra Injection, immune globulin (hizentra), 100 mg
J1561	Gammaked Injection, immune globulin, (Gamunex/Gamunex-C/Gammaked), nonlyophilized (e.g., liquid), 500 mg
J1561	Gamunex-C Injection, immune globulin, (Gamunex/Gamunex-C/Gammaked), nonlyophilized (e.g., liquid), 500 mg
J1566	Gammagard S/D Injection, immune globulin, intravenous, lyophilized (e.g., powder), not otherwise specified, 500 mg
J1568	Octagam Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg
J1569	Gammagard Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg
J1572	Flebogamma; Flebogamma DIF Injection, immune globulin, (Flebogamma/Flebogamma Dif), intravenous, nonlyophilized (e.g., liquid), 500 mg
J1575	Hyqvia Injection, immune globulin/hyaluronidase, (hyqvia), 100 mg immune globulin
J1576	Panzyga Injection, immune globulin (panzyga), intravenous, non-lyophilized (e.g., liquid), 500 mg
J3590	Qivigy (immune globulin intravenous, human – kthm) Unclassified biologics
96365	Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour
96366	Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour (List separately in addition to code for primary procedure)

96369	Subcutaneous infusion for therapy or prophylaxis (specify substance or drug); initial, up to 1 hour, including pump set-up and establishment of subcutaneous infusion site(s)
96370	Subcutaneous infusion for therapy or prophylaxis (specify substance or drug); each additional hour (List separately in addition to code for primary procedure)
96371	Subcutaneous infusion for therapy or prophylaxis (specify substance or drug); additional pump set-up with establishment of new subcutaneous infusion site(s) (List separately in addition to code for primary procedure)
S9338	Home infusion therapy, immunotherapy, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem
ICD-10 codes considered medically necessary if criteria are met:	
Code	*Description*
A01.02	Typhoid fever with heart involvement
A02.1	Salmonella sepsis
A04.71	Enterocolitis due to Clostridium difficile, recurrent
A04.72	Enterocolitis due to Clostridium difficile, not specified as recurrent
A18.84	Tuberculosis of heart
A22.7	Anthrax sepsis
A24.1	Acute and fulminating melioidosis
A26.7	Erysipelothrix sepsis
A32.7	Listerial sepsis
A35	Other tetanus
A36.81	Diphtheritic cardiomyopathy
A38.1	Scarlet fever with myocarditis
A39.4	Meningococcemia, unspecified
A39.52	Meningococcal myocarditis
A39.53	Meningococcal pericarditis
A39.81	Meningococcal encephalitis
A40.0	Sepsis due to streptococcus, group A
A40.1	Sepsis due to streptococcus, group B
A40.3	Sepsis due to Streptococcus pneumoniae
A40.8	Other streptococcal sepsis
A40.9	Streptococcal sepsis, unspecified
A41.01	Sepsis due to Methicillin susceptible Staphylococcus aureus
A41.02	Sepsis due to Methicillin resistant Staphylococcus aureus

A41.1	Sepsis due to other specified staphylococcus
A41.2	Sepsis due to unspecified staphylococcus
A41.3	Sepsis due to Hemophilus influenzae
A41.4	Sepsis due to anaerobes
A41.50	Gram-negative sepsis, unspecified
A41.51	Sepsis due to Escherichia coli
A41.52	Sepsis due to Pseudomonas
A41.53	Sepsis due to Serratia
A41.54	Sepsis due to Acinetobacter baumannii
A41.59	Other Gram-negative sepsis
A41.81	Sepsis due to Enterococcus
A41.89	Other specified sepsis
A41.9	Sepsis, unspecified organism
A42.7	Actinomycotic sepsis
A48.3	Toxic shock syndrome
A52.06	Other syphilitic heart involvement
A52.14	Late syphilitic encephalitis
A54.83	Gonococcal heart infection
A54.86	Gonococcal sepsis
A83.0	Japanese encephalitis
A83.1	Western equine encephalitis
A83.2	Eastern equine encephalitis
A83.3	St Louis encephalitis
A83.4	Australian encephalitis
A83.5	California encephalitis
A83.6	Rocio virus disease
A83.8	Other mosquito-borne viral encephalitis
A83.9	Mosquito-borne viral encephalitis, unspecified
A84.0	Far Eastern tick-borne encephalitis
A84.1	Central European tick-borne encephalitis
A84.81	Powassan virus disease
A84.89	Other tick-borne viral encephalitis
A84.9	Tick-borne viral encephalitis, unspecified

A85.2	Arthropod-borne viral encephalitis, unspecified
B01.0	Varicella meningitis
B01.11	Varicella encephalitis and encephalomyelitis
B01.12	Varicella myelitis
B01.2	Varicella pneumonia
B01.81	Varicella keratitis
B01.89	Other varicella complications
B01.9	Varicella without complication
B05.0	Measles complicated by encephalitis
B05.1	Measles complicated by meningitis
B05.2	Measles complicated by pneumonia
B05.3	Measles complicated by otitis media
B05.4	Measles with intestinal complications
B10.01	Human herpesvirus 6 encephalitis
B10.09	Other human herpesvirus encephalitis
B26.2	Mumps encephalitis
B26.82	Mumps myocarditis
B33.22	Viral myocarditis
B33.23	Viral pericarditis
B37.7	Candidal sepsis
B57.0	Acute Chagas' disease with heart involvement
B57.2	Chagas' disease (chronic) with heart involvement
B58.81	Toxoplasma myocarditis
B97.4	Respiratory syncytial virus as the cause of diseases classified elsewhere
D59.11	Warm autoimmune hemolytic anemia
D59.13	Mixed type autoimmune hemolytic anemia
D59.19	Other autoimmune hemolytic anemia
D59.9	Acquired hemolytic anemia, unspecified
D61.01	Constitutional (pure) red blood cell aplasia
D61.02	Shwachman-Diamond syndrome
D61.03	Fanconi anemia
D61.09	Other constitutional aplastic anemia
D61.1	Drug-induced aplastic anemia
D61.2	Aplastic anemia due to other external agents

D61.3	Idiopathic aplastic anemia
D61.810	Antineoplastic chemotherapy induced pancytopenia
D61.811	Other drug-induced pancytopenia
D61.818	Other pancytopenia
D61.82	Myelophthisis
D61.89	Other specified aplastic anemias and other bone marrow failure syndromes
D61.9	Aplastic anemia, unspecified
D69.2	Other nonthrombocytopenic purpura
D69.3	Immune thrombocytopenic purpura
D69.41	Evans syndrome
D69.42	Congenital and hereditary thrombocytopenia purpura
D69.49	Other primary thrombocytopenia
D69.51	Posttransfusion purpura
D69.59	Other secondary thrombocytopenia
D69.6	Thrombocytopenia, unspecified
D70.8	Other neutropenia
D75.821	Non-immune heparin-induced thrombocytopenia
D75.822	Immune-mediated heparin-induced thrombocytopenia
D75.828	Other heparin-induced thrombocytopenia syndrome
D75.829	Heparin-induced thrombocytopenia, unspecified
D80.0	Hereditary hypogammaglobulinemia
D80.1	Nonfamilial hypogammaglobulinemia
D80.2	Selective deficiency of immunoglobulin A [IgA]
D80.3	Selective deficiency of immunoglobulin G [IgG] subclasses
D80.4	Selective deficiency of immunoglobulin M [IgM]
D80.5	Immunodeficiency with increased immunoglobulin M [IgM]
D80.6	Antibody deficiency with near-normal immunoglobulins or with hyperimmunoglobulinemia
D80.7	Transient hypogammaglobulinemia of infancy
D80.8	Other immunodeficiencies with predominantly antibody defects
D80.9	Immunodeficiency with predominantly antibody defects, unspecified
D81.0	Severe combined immunodeficiency [SCID] with reticular dysgenesis
D81.1	Severe combined immunodeficiency [SCID] with low T- and B-cell numbers
D81.2	Severe combined immunodeficiency [SCID] with low or normal B-cell numbers

D81.31	Severe Combined Immunodeficiency Due To Adenosine Deaminase Deficiency
D81.4	Nezelof's syndrome
D81.5	Purine nucleoside phosphorylase [PNP] deficiency
D81.6	Major histocompatibility complex class I deficiency
D81.7	Major histocompatibility complex class II deficiency
D81.82	Activated Phosphoinositide 3-Kinase Delta Syndrome [Apds]
D81.89	Other combined immunodeficiencies
D81.9	Combined immunodeficiency, unspecified
D82.0	Wiskott-Aldrich syndrome
D82.1	Di George's syndrome
D82.2	Immunodeficiency with short-limbed stature
D82.3	Immunodeficiency following hereditary defective response to Epstein-Barr virus
D82.4	Hyperimmunoglobulin E [IgE] syndrome
D82.8	Immunodeficiency associated with other specified major defects
D82.9	Immunodeficiency associated with major defect, unspecified
D83.0	Common variable immunodeficiency with predominant abnormalities of B-cell numbers and function
D83.1	Common variable immunodeficiency with predominant immunoregulatory T-cell disorders
D83.2	Common variable immunodeficiency with autoantibodies to B- or T-cells
D83.8	Other common variable immunodeficiencies
D83.9	Common variable immunodeficiency, unspecified
D84.9	Immunodeficiency, unspecified
D86.85	Sarcoid myocarditis
E80.4	Gilbert syndrome
E80.5	Crigler-Najjar syndrome
E80.6	Other disorders of bilirubin metabolism
E80.7	Disorder of bilirubin metabolism, unspecified
G04.00	Acute disseminated encephalitis and encephalomyelitis, unspecified
G04.01	Postinfectious acute disseminated encephalitis and encephalomyelitis (postinfectious ADEM)
G04.02	Postimmunization acute disseminated encephalitis, myelitis and encephalomyelitis
G04.31	Postinfectious acute necrotizing hemorrhagic encephalopathy
G05.3	Encephalitis and encephalomyelitis in diseases classified elsewhere

G11.3	Cerebellar ataxia with defective DNA repair
G25.82	Stiff-man syndrome
G35	Multiple sclerosis
G35.D	Multiple sclerosis, unspecified
G61.0	Guillain-Barre syndrome
G61.81	Chronic inflammatory demyelinating polyneuritis
G61.82	Multifocal motor neuropathy
G70.00	Myasthenia gravis without (acute) exacerbation
G70.01	Myasthenia gravis with (acute) exacerbation
G70.2	Congenital and developmental myasthenia
G70.80	Lambert-Eaton syndrome, unspecified
G70.81	Lambert-Eaton syndrome in disease classified elsewhere
G73.1	Lambert-Eaton syndrome in neoplastic disease
G93.41	Metabolic encephalopathy
I01.0	Acute rheumatic pericarditis
I01.2	Acute rheumatic myocarditis
I02.0	Rheumatic chorea with heart involvement
I02.9	Rheumatic chorea without heart involvement
I09.0	Rheumatic myocarditis
I09.2	Chronic rheumatic pericarditis
I24.1	Dressler's syndrome
I30.0	Acute nonspecific idiopathic pericarditis
I30.1	Infective pericarditis
I30.8	Other forms of acute pericarditis
I30.9	Acute pericarditis, unspecified
I31.0	Chronic adhesive pericarditis
I31.1	Chronic constrictive pericarditis
I31.8	Other specified diseases of pericardium
I31.9	Disease of pericardium, unspecified
I32	Pericarditis in diseases classified elsewhere
I33.9	Acute and subacute endocarditis, unspecified
I40.0	Infective myocarditis
I40.1	Isolated myocarditis
I40.8	Other acute myocarditis

I40.9	Acute myocarditis, unspecified
I41	Myocarditis in diseases classified elsewhere
I51.4	Myocarditis, unspecified
I97.0	Postcardiotomy syndrome
J09.X9	Influenza due to identified novel influenza A virus with other manifestations
J10.82	Influenza due to other identified influenza virus with myocarditis
J11.82	Influenza due to unidentified influenza virus with myocarditis
J12.1	Respiratory syncytial virus pneumonia
J20.5	Acute bronchitis due to respiratory syncytial virus
J21.0	Acute bronchiolitis due to respiratory syncytial virus
J84.01	Alveolar proteinosis
J84.02	Pulmonary alveolar microlithiasis
J84.03	Idiopathic pulmonary hemosiderosis
J84.09	Other alveolar and parieto-alveolar conditions
J84.10	Pulmonary fibrosis, unspecified
J84.115	Respiratory bronchiolitis interstitial lung disease
J84.170	Interstitial lung disease with progressive fibrotic phenotype in diseases classified elsewhere
J84.178	Other interstitial pulmonary diseases with fibrosis in diseases classified elsewhere
J84.82	Adult pulmonary Langerhans cell histiocytosis
J84.83	Surfactant mutations of the lung
J84.841	Neuroendocrine cell hyperplasia of infancy
J84.842	Pulmonary interstitial glycogenosis
J84.843	Alveolar capillary dysplasia with vein misalignment
J84.848	Other interstitial lung diseases of childhood
J84.89	Other specified interstitial pulmonary diseases
J84.9	Interstitial pulmonary disease, unspecified
L10.0	Pemphigus vulgaris
L10.1	Pemphigus vegetans
L10.2	Pemphigus foliaceous
L10.3	Brazilian pemphigus
L10.4	Pemphigus erythematosus
L10.5	Drug-induced pemphigus
L10.81	Paraneoplastic pemphigus

L10.89	Other pemphigus
L10.9	Pemphigus, unspecified
L51.1	Stevens-Johnson syndrome
L51.2	Toxic epidermal necrolysis [Lyell]
L51.3	Stevens-Johnson syndrome-toxic epidermal necrolysis overlap syndrome
L94.4	Gottron's papules
M05.30	Rheumatoid heart disease with rheumatoid arthritis of unspecified site
M05.311	Rheumatoid heart disease with rheumatoid arthritis of right shoulder
M05.312	Rheumatoid heart disease with rheumatoid arthritis of left shoulder
M05.319	Rheumatoid heart disease with rheumatoid arthritis of unspecified shoulder
M05.321	Rheumatoid heart disease with rheumatoid arthritis of right elbow
M05.322	Rheumatoid heart disease with rheumatoid arthritis of left elbow
M05.329	Rheumatoid heart disease with rheumatoid arthritis of unspecified elbow
M05.331	Rheumatoid heart disease with rheumatoid arthritis of right wrist
M05.332	Rheumatoid heart disease with rheumatoid arthritis of left wrist
M05.339	Rheumatoid heart disease with rheumatoid arthritis of unspecified wrist
M05.341	Rheumatoid heart disease with rheumatoid arthritis of right hand
M05.342	Rheumatoid heart disease with rheumatoid arthritis of left hand
M05.349	Rheumatoid heart disease with rheumatoid arthritis of unspecified hand
M05.351	Rheumatoid heart disease with rheumatoid arthritis of right hip
M05.352	Rheumatoid heart disease with rheumatoid arthritis of left hip
M05.359	Rheumatoid heart disease with rheumatoid arthritis of unspecified hip
M05.361	Rheumatoid heart disease with rheumatoid arthritis of right knee
M05.362	Rheumatoid heart disease with rheumatoid arthritis of left knee
M05.369	Rheumatoid heart disease with rheumatoid arthritis of unspecified knee
M05.371	Rheumatoid heart disease with rheumatoid arthritis of right ankle and foot
M05.372	Rheumatoid heart disease with rheumatoid arthritis of left ankle and foot
M05.379	Rheumatoid heart disease with rheumatoid arthritis of unspecified ankle and foot
M05.39	Rheumatoid heart disease with rheumatoid arthritis of multiple sites
M30.3	Mucocutaneous lymph node syndrome [Kawasaki]
M31.10	Thrombotic microangiopathy, unspecified
M31.11	Hematopoietic stem cell transplantation-associated thrombotic microangiopathy
M31.19	Other thrombotic microangiopathy
M31.30	Wegener's granulomatosis without renal involvement

M31.31	Wegener's granulomatosis with renal involvement
M31.7	Microscopic polyangiitis
M32.12	Pericarditis in systemic lupus erythematosus
M33.00	Juvenile dermatomyositis, organ involvement unspecified
M33.01	Juvenile dermatomyositis with respiratory involvement
M33.02	Juvenile dermatomyositis with myopathy
M33.03	Juvenile dermatomyositis without myopathy
M33.09	Juvenile dermatomyositis with other organ involvement
M33.10	Other dermatomyositis, organ involvement unspecified
M33.11	Other dermatomyositis with respiratory involvement
M33.12	Other dermatomyositis with myopathy
M33.13	Other dermatomyositis without myopathy
M33.19	Other dermatomyositis with other organ involvement
M33.20	Polymyositis, organ involvement unspecified
M33.21	Polymyositis with respiratory involvement
M33.22	Polymyositis with myopathy
M33.29	Polymyositis with other organ involvement
M33.90	Dermatopolymyositis, unspecified, organ involvement unspecified
M33.91	Dermatopolymyositis, unspecified with respiratory involvement
M33.92	Dermatopolymyositis, unspecified with myopathy
M33.93	Dermatopolymyositis, unspecified without myopathy
M33.99	Dermatopolymyositis, unspecified with other organ involvement
M35.81	Multisystem inflammatory syndrome
M35.89	Other specified systemic involvement of connective tissue
M36.0	Dermato(poly)myositis in neoplastic disease
N18.9	Chronic kidney disease, unspecified
O03.37	Sepsis following incomplete spontaneous abortion
O03.87	Sepsis following complete or unspecified spontaneous abortion
O04.87	Sepsis following (induced) termination of pregnancy
O07.37	Sepsis following failed attempted termination of pregnancy
O08.82	Sepsis following ectopic and molar pregnancy
O14.20	HELLP syndrome (HELLP), unspecified trimester
O14.22	HELLP syndrome (HELLP), second trimester
O14.23	HELLP syndrome (HELLP), third trimester

O14.24	HELLP syndrome, complicating childbirth
O14.25	HELLP syndrome, complicating the puerperium
O36.8210	Fetal anemia and thrombocytopenia, first trimester, not applicable or unspecified
O36.8211	Fetal anemia and thrombocytopenia, first trimester, fetus 1
O36.8212	Fetal anemia and thrombocytopenia, first trimester, fetus 2
O36.8213	Fetal anemia and thrombocytopenia, first trimester, fetus 3
O36.8214	Fetal anemia and thrombocytopenia, first trimester, fetus 4
O36.8215	Fetal anemia and thrombocytopenia, first trimester, fetus 5
O36.8219	Fetal anemia and thrombocytopenia, first trimester, other fetus
O36.8220	Fetal anemia and thrombocytopenia, second trimester, not applicable or unspecified
O36.8221	Fetal anemia and thrombocytopenia, second trimester, fetus 1
O36.8222	Fetal anemia and thrombocytopenia, second trimester, fetus 2
O36.8223	Fetal anemia and thrombocytopenia, second trimester, fetus 3
O36.8224	Fetal anemia and thrombocytopenia, second trimester, fetus 4
O36.8225	Fetal anemia and thrombocytopenia, second trimester, fetus 5
O36.8229	Fetal anemia and thrombocytopenia, second trimester, other fetus
O36.8230	Fetal anemia and thrombocytopenia, third trimester, not applicable or unspecified
O36.8231	Fetal anemia and thrombocytopenia, third trimester, fetus 1
O36.8232	Fetal anemia and thrombocytopenia, third trimester, fetus 2
O36.8233	Fetal anemia and thrombocytopenia, third trimester, fetus 3
O36.8234	Fetal anemia and thrombocytopenia, third trimester, fetus 4
O36.8235	Fetal anemia and thrombocytopenia, third trimester, fetus 5
O36.8239	Fetal anemia and thrombocytopenia, third trimester, other fetus
O36.8290	Fetal anemia and thrombocytopenia, unspecified trimester, not applicable or unspecified
O36.8291	Fetal anemia and thrombocytopenia, unspecified trimester, fetus 1
O36.8292	Fetal anemia and thrombocytopenia, unspecified trimester, fetus 2
O36.8293	Fetal anemia and thrombocytopenia, unspecified trimester, fetus 3
O36.8294	Fetal anemia and thrombocytopenia, unspecified trimester, fetus 4
O36.8295	Fetal anemia and thrombocytopenia, unspecified trimester, fetus 5
O36.8299	Fetal anemia and thrombocytopenia, unspecified trimester, other fetus
O75.3	Other infection during labor
O85	Puerperal sepsis

O86.04	Sepsis following an obstetrical procedure
O98.511	Other viral diseases complicating pregnancy, first trimester
O98.512	Other viral diseases complicating pregnancy, second trimester
O98.513	Other viral diseases complicating pregnancy, third trimester
O98.519	Other viral diseases complicating pregnancy, unspecified trimester
P36.0	Sepsis of newborn due to streptococcus, group B
P36.10	Sepsis of newborn due to unspecified streptococci
P36.19	Sepsis of newborn due to other streptococci
P36.2	Sepsis of newborn due to Staphylococcus aureus
P36.30	Sepsis of newborn due to unspecified staphylococci
P36.39	Sepsis of newborn due to other staphylococci
P36.4	Sepsis of newborn due to Escherichia coli
P36.5	Sepsis of newborn due to anaerobes
P36.8	Other bacterial sepsis of newborn
P36.9	Bacterial sepsis of newborn, unspecified
P55.8	Other hemolytic diseases of newborn
P57.0	Kernicterus due to isoimmunization
P57.8	Other specified kernicterus
P57.9	Kernicterus, unspecified
P58.0	Neonatal jaundice due to bruising
P58.1	Neonatal jaundice due to bleeding
P58.2	Neonatal jaundice due to infection
P58.3	Neonatal jaundice due to polycythemia
P58.41	Neonatal jaundice due to drugs or toxins transmitted from mother
P58.42	Neonatal jaundice due to drugs or toxins given to newborn
P58.5	Neonatal jaundice due to swallowed maternal blood
P58.8	Neonatal jaundice due to other specified excessive hemolysis
P58.9	Neonatal jaundice due to excessive hemolysis, unspecified
P59.0	Neonatal jaundice associated with preterm delivery
P61.0	Transient neonatal thrombocytopenia
P94.0	Transient neonatal myasthenia gravis
R17	Unspecified jaundice
R65.20	Severe sepsis without septic shock

R65.21	Severe sepsis with septic shock
R76.89	Other specified abnormal immunological findings in serum
T45.1X5A	Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter
T45.1X5D	Adverse effect of antineoplastic and immunosuppressive drugs, subsequent encounter
T81.44XA	Sepsis following a procedure, initial encounter
T81.44XD	Sepsis following a procedure, subsequent encounter
T81.44XS	Sepsis following a procedure, sequela
T86.10	Unspecified complication of kidney transplant
T86.11	Kidney transplant rejection
T86.20	Unspecified complication of heart transplant
T86.21	Heart transplant rejection
T86.290	Cardiac allograft vasculopathy
T86.30	Unspecified complication of heart-lung transplant
T86.31	Heart-lung transplant rejection
T86.40	Unspecified complication of liver transplant
T86.41	Liver transplant rejection
T86.810	Lung transplant rejection
T86.819	Unspecified complication of lung transplant
T86.850	Intestine transplant rejection
T86.890	Other transplanted tissue rejection
Z20.4	Contact with and (suspected) exposure to rubella
Z20.5	Contact with and (suspected) exposure to viral hepatitis
Z20.820	Contact with and (suspected) exposure to varicella
Z23	Encounter for immunization
Z41.8	Encounter for other procedures for purposes other than remedying health state

References

1. Anderson CR, Olson JA. Correlation of weight-based i.v. immune globulin doses with changes in serum immunoglobulin G levels. Am J Health Syst Pharm. 2015 Feb 15;72(4):285-9. doi: 10.2146/ajhp140171. PMID: 25631835.
2. Alyglo (immune globulin intravenous [human]) [prescribing information]. Teaneck, NJ: GC Biopharma USA; December 2023.
3. Berger M. Choices in IgG replacement therapy for primary immune deficiency diseases: subcutaneous IgG vs. intravenous IgG and selecting an optimal dose. Curr Opin Allergy Clin Immunol. 2011 Dec;11(6):532-8. doi: 10.1097/ACI.0b013e32834c22da. PMID: 21971330.

4. Bivigam (immune globulin intravenous [human]) [prescribing information]. Boca Raton, FL: ADMA Biologics; March 2024.
5. Cuvitru (immune globulin subcutaneous [human]) [prescribing information]. Lexington, MA: Takeda Pharmaceuticals USA Inc; March 2023.
6. Flebogamma 5% DIF (immune globulin intravenous [human]) [prescribing information]. Barcelona, Spain: Instituto Grifols, SA; August 2024.
7. Gammagard Liquid (immune globulin intravenous and subcutaneous [human]) [prescribing information]. Lexington, MA: Takeda Pharmaceuticals USA Inc; January 2024.
8. Gammagard S/D (immune globulin intravenous [human]) [prescribing information]. Lexington, MA: Takeda Pharmaceuticals; March 2023.
9. Grindeland JW, Grindeland CJ, Moen C, Leedahl ND, Leedahl DD. Outcomes Associated With Standardized Ideal Body Weight Dosing of Intravenous Immune Globulin in Hospitalized Patients: A Multicenter Study. Ann Pharmacother. 2020 Mar;54(3):205-212. doi: 10.1177/1060028019880300. Epub 2019 Oct 3.
10. Hizentra (immune globulin) [prescribing information]. Kankakee, IL: CSL Behring LLC; April 2023.
11. Hodkinson JP. Considerations for dosing immunoglobulin in obese patients. Clin Exp Immunol. 2017 Jun;188(3):353-362. doi: 10.1111/cei.12955. Epub 2017 Apr 17.
12. Hodkinson JP, Lucas M, Lee M, Harrison M, Lunn MP, Chapel H. Therapeutic immunoglobulin should be dosed by clinical outcome rather than by body weight in obese patients. Clin Exp Immunol. 2015 Jul;181(1):179-87. doi: 10.1111/cei.12616. Epub 2015 May 25.
13. Hyqvia (immune globulin infusion 10% [human] with recombinant human hyaluronidase) [prescribing information]. Lexington, MA: Takeda Pharmaceuticals USA Inc; January 2024.
14. Lagasse C, Hatton RC, Pyles E. A survey of intravenous immune globulin (IVIG) dosing strategies. Ann Pharmacother. 2015 Feb;49(2):254-7. doi: 10.1177/1060028014559095.
15. Li Z, Mahmood I. Immunoglobulin therapies for primary immunodeficiency diseases (part 2): considerations for dosing strategies. Immunotherapy. 2024;16(13):895-905. doi: 10.1080/1750743X.2024.2382074. Epub 2024 Sep 26. PMID: 39323406; PMCID: PMC11457668.
16. Li Z, McCoy B, Engl W, Yel L. Steady-State Serum IgG Trough Levels Are Adequate for Pharmacokinetic Assessment in Patients with Immunodeficiencies Receiving Subcutaneous Immune Globulin. J Clin Immunol. 2021 Aug;41(6):1331-1338. doi: 10.1007/s10875-021-00990-z. Epub 2021 May 26. PMID: 34036490; PMCID: PMC8310849.
17. Mahmood I, Li Z. Immunoglobulin therapies for primary immunodeficiency diseases (part 1): understanding the pharmacokinetics. Immunotherapy. 2024;16(13):879-894. doi: 10.1080/1750743X.2024.2382081. Epub 2024 Sep 26. PMID: 39323402; PMCID: PMC11457669.
18. Nguyen TP, Nguyen TD, Zhu L, et al. Precision Intravenous Immunoglobulin Dosing and Clinical Outcomes: A Retrospective Chart Review. J Clin Neuromuscul Dis. 2021 Sep 1;23(1):18-23. doi: 10.1097/CND.0000000000000359.
19. Octagam 10% (immune globulin intravenous [human]) [prescribing information]. New York, NY: Pfizer Labs; January 2024.
20. Otani IM, Lehman HK, Jongco AM, Tsao LR, Azar AE, Tarrant TK, Engel E, Walter JE, Truong TQ, Khan DA, Ballow M, Cunningham-Rundles C, Lu H, Kwan M, Barmettler S. Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: A Work Group Report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees. J Allergy Clin Immunol. 2022 May;149(5):1525-1560. doi: 10.1016/j.jaci.2022.01.025. Epub 2022 Feb 14. PMID: 35176351.
21. Pecoraro A, Ricci S, Vultaggio A, Boggia GM, Spadaro G; SHIFT and IBIS Study Groups. Correlations Among Subcutaneous Immunoglobulin Dosage, Immunoglobulin G Serum Pre-infusional Levels and Body Mass Index in Primary Antibody Deficiency Patients: A Pooled Analysis from the SHIFT/IBIS Studies. Clin Drug Investig. 2020 Mar;40(3):279-286. doi: 10.1007/s40261-020-00885-8.
22. Stump SE, Schepers AJ, Jones AR, Alexander MD, Auten JJ. Comparison of Weight-Based Dosing Strategies for Intravenous Immunoglobulin in Patients with Hematologic Malignancies.

Pharmacotherapy. 2017 Dec;37(12):1530-1536. doi: 10.1002/phar.2047. Epub 2017 Nov 27. PMID: 29028117.
23. Wimperis J, Lunn M, Jones A, et al. National Health Service. Clinical guidelines for immunoglobulin use: second edition update. July 2011. Available at: https://assets.publishing.service.gov.uk/media/682df684c054883884bff3c3/dh_131107-under-review-2025.pdf. Accessed 3 March 2026.
24. Xembify (immune globulin subcutaneous [human-klhw]) [prescribing information]. Research Triangle Park, NC: Grifols Therapeutics LLC; July 2024.
25. Zhou T, Tegenge MA, Golding B, Scott J. Dosing Strategy of Immunoglobulin (IgG) Replacement Therapies in Obese and Overweight Patients with Primary Immunodeficiency Diseases (PIDDs): A Meta-Analysis of Clinical Trials. J Clin Pharmacol. 2023 Nov;63 Suppl 2:S110-S116. doi: 10.1002/jcph.2368. PMID: 37942903.

Appendix A: Weight-Based Dosing Calculations

The following standardized calculations should be used when determining appropriate dosing weights:

Table 1: Weight-Based Dosing Formulas

Type of Weight	Formula	Notes
Ideal Body Weight (IBW) - Male	50 kg + [2.3 × (height in inches - 60)]	For height >5 feet (60 inches)
	50 kg - [2.3 × (60 - height in inches)]	For height <5 feet (60 inches)
Ideal Body Weight (IBW) - Female	45.5 kg + [2.3 × (height in inches - 60)]	For height >5 feet (60 inches)
	45.5 kg - [2.3 × (60 - height in inches)]	For height <5 feet (60 inches)
Adjusted Body Weight (adjBW)	IBW + [0.4 × (actual weight - IBW)]	For *members* >120% IBW

Examples:

1. *Male member, 5'10" (70 inches):*
    - *IBW = 50 kg + [2.3 × (70 - 60)] = 73 kg*
2. *Female member, 5'6" (66 inches):*
    - *IBW = 45.5 kg + [2.3 × (66 - 60)] = 59.3 kg*
3. *Member with IBW of 60 kg and actual weight of 90 kg:*
    - *adjBW = 60 + [0.4 × (90 - 60)] = 72 kg*

Clinical Guideline Revision / History Information

Original Date: 06/01/2025
Reviewed/Revised: 05/01/2026